glp 1 gip dual agonist weight loss GIPR/GLP-1R therapies for diabetes and loss—chemistry, physiology, and clinical applications Dual and Triple Gut Peptide

Future GLP-1 Medications in Canada The GLP-1 space is moving fast

Combination Therapy: DPP-4 inhibitors may be used as monotherapy in individuals with mild to moderate diabetes who are non-compliant or intolerant of metformin and other first-line agents

The majority of these therapies aim to replicate or inhibit the effects of various gut hormones such as GLP-1, GIP, amylin, and glucagon [27, 28]

Rapid weight loss, however, can also cause bone density loss

You can use MeAgain with or instead of Glapp If you already use Glapp, the useful habits transfer naturally: logging doses, watching symptoms, noticing hunger or food noise, and paying attention to how the medication feels over time

The most common side effects are gastrointestinal, including nausea and vomiting, which often improve over time